Radioimmunotherapy (RIT) in Brain Tumors
10.1007/s13139-019-00618-6
- Author:
Ali GHOLAMREZANEZHAD
1
;
Hossein SHOOLI
;
Narges JOKAR
;
Reza NEMATI
;
Majid ASSADI
Author Information
1. Department of Diagnostic Radiology, Keck School of Medicine, University of Southern California (USC), 1520 San Pablo Street, Suite L1600, Los Angeles, CA 90033, USA.
- Publication Type:Review
- Keywords:
Radioimmunotherapy (RIT);
Brain tumors;
Monoclonal antibody (mAb)
- MeSH:
Brain Neoplasms;
Brain;
Humans;
Incidence;
Precision Medicine;
Prognosis;
Radioimmunotherapy;
Tumor Microenvironment
- From:Korean Journal of Nuclear Medicine
2019;53(6):374-381
- CountryRepublic of Korea
- Language:English
-
Abstract:
Annually, the incidence of brain tumors has slightly increased and also the patient prognosis is still disappointing, especially for high-grade neoplasms. So, researchers seek methods to improve therapeutic index as a critical aim of treatment. One of these new challenging methods is radioimmunotherapy (RIT) that involves recruiting a coupling of radionuclide component with monoclonal antibody (mAb) which are targeted against cell surface tumor–related antigens or antigens of cells within the tumor microenvironment. In the context of cancer care, precision medicine is exemplified by RIT; precision medicine can offer a tailored treatment to meet the needs for treatment of brain tumors. This review aims to discuss the molecular targets used in radioimmunotherapy of brain tumors, available and future radioimmunopharmaceutics, clinical trials of radioimmunotherapy in brain neoplasms, and eventually, conclusion and future perspective of application of radioimmunotherapy in neurooncology cancer care.
